As Rubraca faces questions in ovarian cancer, Clovis trots out a prostate cancer partial win

Clovis Oncology is already fighting the FDA over expanding Rubraca into an earlier treatment line in ovarian cancer. Now, the company hopes the U.S. regulator could allow the troubled PARP inhibitor a similar move in prostate cancer—but the situation is complicated.